International Journal of Hyperthermia · Available online 28 Jul 2026 · In press · DOI 10.1080/02656736.2026.2692414
Pernille B. Elming, Patricia S. Nielsen, Jan Alsner, Michael R. Horsman
Background and purpose This was a pre‐clinical study designed to investigate the potential of combining hyperthermia with checkpoint inhibitors.Material and methods C3H mammary carcinomas, grown in the right rear foot of CDF1 mice, were treated when tumors reached 200 mm3. Hyperthermia (39.5‐42.5 °C for 30‐120 min) was applied following immersion of the tumor bearing leg into a circulating water bath. The checkpoint inhibitors were anti‐CTLA‐4/PD‐1/PD‐L1 antibodies injected intraperitoneally (4 x 10 mg/kg). Tumor growth was monitored daily and the treatment endpoint was TGT5 (time for tumors to regrow to 5 times treatment volume).Results None of the antibodies alone affected TGT5 when compared to controls. However, while neither the anti‐PD‐1 nor anti‐PD‐L1 antibodies influenced heat response, an enhanced effect was found with the anti‐CTLA‐4 antibody. This was most apparent when tumors were heated once at 42.5 °C for 1‐hour on day 0 and the antibody administered on days 1, 4, 8 and 11 or 1, 2, 3 and 4 after heating. However, the responses were heterogenous with some animals treated with heat and anti-CTLA-4 showing an increase in TGT5 compared to heat alone, while others showed no change. Mechanistic studies of tumor blood perfusion and infiltrating lymphocytes in tissue sections showed a substantial decrease reaching a nadir 1-3 days after heating, with recovery by 7‐10 days.Conclusions Under specific conditions, there appeared to be an enhanced anti-tumor effect with the hyperthermia-checkpoint inhibitor combination, but these effects were often sporadic. Mechanisms for the interaction between heat and the anti‐CTLA‐4 antibody remain unclear.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Elming, P., Nielsen, P., Alsner, J., et al. (2026). An exploratory pre-clinical study of the combination of hyperthermia and checkpoint inhibitors. International Journal of Hyperthermia. https://doi.org/10.1080/02656736.2026.2692414